Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
Ursina B. M. Begré, Markus Jörger, Stefan Aebi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21

Showing 21 citing articles:

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
Mirjam de With, A. Sadlon, Erika Cecchin, et al.
ESMO Open (2023) Vol. 8, Iss. 2, pp. 101197-101197
Open Access | Times Cited: 43
Balance of care activity after EMA recommendation for DPYD gene testing in Galicia
Almudena Gil-Rodríguez, Sheila Recarey-Rama, Ana Rodríguez-Viyuela, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center
Megan Muldoon, Mollie Beck, Nichlas Sebree, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 2
Open Access | Times Cited: 7
Pharmacogenomics in the era of personalised medicine
Cassandra White, Rodney J. Scott, Christine Paul, et al.
The Medical Journal of Australia (2022) Vol. 217, Iss. 10, pp. 510-513
Open Access | Times Cited: 22
Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
Anthi Maslarinou, Vangelis G. Manolopoulos, Georgia Ragia
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
Alessia Bignucolo, Elena De Mattia, Rossana Roncato, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
Pharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data
Nina L Wittwer, Christoph Meier, Carola A. Huber, et al.
Drug Safety (2025)
Open Access
Differences in DPYD Population Frequencies Observed in Galicians Compared to Europeans and Spanish from PhotoDPYD Study
Almudena Gil-Rodríguez, Sheila Recarey-Rama, Ana Rodríguez-Viyuela, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 515-515
Open Access
Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study
Cassandra White, Christine Paul, Esther Liet, et al.
Internal Medicine Journal (2025)
Closed Access
Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?
Elena Peruzzi, Rossana Roncato, Elena De Mattia, et al.
British Journal of Clinical Pharmacology (2023)
Open Access | Times Cited: 8
Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
Georgia Ragia, Anthi Maslarinou, Natalia Atzemian, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Overcoming Barriers: Strategies for Implementing Pharmacist-Led Pharmacogenetic Services in Swiss Clinical Practice
Florine M. Wiss, Deborah Jakober, Markus L. Lampert, et al.
Genes (2024) Vol. 15, Iss. 7, pp. 862-862
Open Access | Times Cited: 2
Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
Angela Wu, H Anderson, Curtis Hughesman, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD)
Alisa Ambrodji, Angélique Sadlon, Ursula Amstutz, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7599-7599
Open Access | Times Cited: 1
Pharmacogenetic Practice of Anticancer Drugs: Multiple Approaches for an Accurate and Comprehensive Genotyping
Cristina Montrasio, Stefania Cheli, Emilio Clementi
Pharmacogenomics and Personalized Medicine (2023) Vol. Volume 16, pp. 739-746
Open Access | Times Cited: 3
Feasibility of DPYD Genotyping in Australian Cancer Patients
Cassandra White, Christine Paul, Esther Liet, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 1
AWARENESS AND RECOMMENDATION RELATED TO DPYD TESTING AMONG MEDICAL ONCOLOGISTS IN ROMANIA: A SURVEY STUDY
Andrada Larisa Deac
FARMACIA (2023) Vol. 71, Iss. 4, pp. 841-847
Open Access | Times Cited: 1
Implementation of DPYD testing in Bulgarian patients with cancer
Nelly Miteva-Marcheva, Hristo Ivanov, Elena Bangieva-Ivanova, et al.
Biotechnology & Biotechnological Equipment (2024) Vol. 38, Iss. 1
Open Access
Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review
Angela Wu, Edward Raack, Colin J.D. Ross, et al.
Therapeutic Drug Monitoring (2024)
Closed Access
Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients
Manuela Pinheiro, Ana Peixoto, Patrícia Rocha, et al.
Pharmacogenetics and Genomics (2023) Vol. 33, Iss. 8, pp. 165-171
Closed Access
Métabolisme des xénobiotiques
Philippe Beaune, Marie‐Anne Loriot
EMC - Hépatologie (2023) Vol. 38, Iss. 4, pp. 1-9
Closed Access
Page 1

Scroll to top